ISU Abxis Co., Ltd. (KOSDAQ:086890)

Market Cap	210.13B
Revenue (ttm)	50.93B
Net Income (ttm)	22.34B
Shares Out	39.50M
EPS (ttm)	514.54
PE Ratio	10.34
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	179,756
Average Volume	114,176
Open	5,290.00
Previous Close	5,320.00
Day's Range	5,260.00 - 5,350.00
52-Week Range	3,945.00 - 7,020.00
Beta	0.63
RSI	48.50
Earnings Date	Aug 8, 2025

About ISU Abxis

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary inte...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2001
• Employees: 178
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086890

Financial Performance

In 2024, ISU Abxis's revenue was 60.26 billion, an increase of 10.96% compared to the previous year's 54.31 billion. Earnings were 14.72 billion, an increase of 307.63%.